Dyspareunia due to menopause is pain during sexual intercourse caused by the physical changes that happen to vaginal tissue when estrogen levels drop. It affects anywhere from 8% to 45% of midlife and postmenopausal women, depending on the population surveyed, and unlike hot flashes, it typically gets worse over time without treatment rather than better.
The pain is not psychological, and it’s not an inevitable part of aging you simply have to accept. It has a clear biological cause and several effective treatments.
Why Estrogen Loss Changes Vaginal Tissue
Estrogen receptors line the vagina, vulva, urethra, and bladder. During your reproductive years, estrogen keeps these tissues thick, elastic, and well-supplied with blood. It also drives a chain reaction that keeps the vagina naturally moist and protected: estrogen prompts vaginal cells to produce glycogen, which friendly bacteria (lactobacilli) convert into lactic acid, maintaining an acidic pH between 3.5 and 5.0. That acidity supports a healthy microbiome and helps prevent infections.
After menopause, this entire system winds down. The vaginal lining thins, sometimes to just a few cell layers. Collagen breaks down, so tissue loses its stretch. Blood flow decreases, which means less natural lubrication. Lactobacilli decline, and vaginal pH rises above 5.0, creating an environment more prone to irritation and infection. The medical term for this collection of changes is genitourinary syndrome of menopause, or GSM, and it affects the vulva, vagina, and urinary tract together.
These changes are progressive. Unlike hot flashes, which often ease within a few years, vaginal atrophy continues as long as estrogen stays low. That’s why many women notice the pain worsening in their 60s compared to their 50s. In the Melbourne Women’s Midlife Health Study, 12% of women around age 50 reported dyspareunia, rising to 17% by age 60.
What the Pain Feels Like
The pain is most commonly felt at the vaginal opening during penetration, often described as burning, stinging, or a raw, sandpaper-like friction. Some women also feel a deeper ache. Dryness is almost always part of the picture, but pain can persist even when using lubrication, because the underlying tissue has become thinner and less resilient.
GSM-related dyspareunia rarely travels alone. In one study of postmenopausal women with moderate to severe pain during sex, 82% also reported urinary symptoms like stress incontinence, urgency, or frequency. About 35% had tenderness in the pelvic floor muscles, which can amplify the pain. If you’re experiencing a combination of vaginal dryness, pain with sex, and urinary changes, these are likely connected to the same estrogen-driven process.
Lubricants vs. Moisturizers
These are first-line, non-hormonal options, and they serve different purposes. Lubricants are applied right before or during sex to reduce friction. They work immediately but their effect is temporary. If dryness bothers you only during intercourse, a lubricant may be enough.
Vaginal moisturizers work differently. You apply them regularly, anywhere from daily to every two or three days depending on severity, and they adhere to the vaginal lining to restore moisture over time. Their effects last two to three days per application. For best results, look for a product that is paraben-free, has an acidic pH (closer to the vagina’s natural range), and has an osmolality below 380 mOsm/kg. High-osmolality products can actually draw water out of tissue cells and cause further irritation. Common effective ingredients include hyaluronic acid, polycarbophil, and glycerin in appropriate concentrations.
Many women use both: a moisturizer for daily comfort and a lubricant during sex.
Vaginal Estrogen Therapy
When lubricants and moisturizers aren’t enough, low-dose vaginal estrogen is the most well-studied treatment. It comes in three forms: creams, tablets, and a flexible ring. All three deliver estrogen directly to vaginal tissue with minimal absorption into the bloodstream, which distinguishes them from systemic hormone therapy (pills or patches that treat hot flashes and affect the whole body).
Vaginal estrogen reverses the changes driving the pain. It thickens the vaginal lining, restores elasticity, brings back moisture, and lowers pH so healthy bacteria can recolonize. In clinical trials, low-dose estradiol cream significantly reduced dyspareunia severity compared to placebo by week 8 of treatment. The typical routine starts with daily application for about two weeks, then drops to twice weekly for maintenance.
Because the dose stays local, vaginal estrogen does not carry the same risk profile as systemic hormone therapy. However, for women with a history of hormone receptor-positive breast cancer, even low-dose vaginal estrogen requires careful consideration. The American College of Obstetricians and Gynecologists notes that systemic estrogen is generally considered contraindicated in this group, and local vaginal options need to be weighed individually.
Other Prescription Options
Two additional prescriptions target menopausal dyspareunia without using traditional estrogen.
The first is an oral tablet (ospemifene) that belongs to a class of drugs called selective estrogen receptor modulators. It acts like estrogen specifically in vaginal tissue, thickening and moisturizing the lining, while behaving differently in breast and uterine tissue. Clinical studies found no significant changes in the uterine lining at the approved dose. It’s taken daily by mouth, which some women prefer over vaginal application.
The second is an intravaginal insert containing DHEA (prasterone), a hormone precursor that vaginal cells convert locally into both estrogen and testosterone. It’s inserted nightly and works directly at the tissue level.
The Role of the Pelvic Floor
Pain during sex doesn’t always come from tissue changes alone. About one-third of postmenopausal women with dyspareunia have measurable tenderness in their pelvic floor muscles. What happens is a cycle: thin, dry tissue causes pain, the pelvic floor muscles tighten in response to protect against that pain, and the tightness itself becomes a source of discomfort. Over time, the muscles can become simultaneously overactive (too tense at rest) and weak.
Pelvic floor physical therapy directly addresses this. In a randomized controlled trial, women who received intravaginal manual techniques, including massage and myofascial release, experienced dramatically reduced pain scores. On a 0-to-10 pain scale, the treatment group improved by an average of 7.3 points compared to the control group. Sexual function scores also improved significantly. These gains held at the three-month follow-up after treatment ended.
Counterintuitively, pelvic floor exercises that include full, strong contractions can actually help reduce resting muscle tension, not increase it. Maximal voluntary contraction has been shown to lower both resting pressure and baseline muscle activity. This is why a trained pelvic floor therapist will often prescribe both strengthening and relaxation work together.
How GSM Is Diagnosed
There is no single test for menopausal dyspareunia. Diagnosis is primarily based on your symptoms and a physical examination. A clinician will look for visible signs of vaginal atrophy: pale, thin tissue that may appear smooth rather than having its normal ridged texture, loss of elasticity, and reduced moisture. Vaginal pH above 5.0 strongly suggests estrogen-related changes. In some cases, a vaginal swab is examined under a microscope to check the ratio of cell types: a shift from mature surface cells to immature deeper-layer cells confirms thinning of the vaginal lining.
Blood tests for estrogen levels are not typically needed. The tissue changes are visible and the symptoms are characteristic enough that most experienced clinicians can make the diagnosis in a single visit. What matters most is that you describe the pain specifically: where you feel it, when it occurs, and whether it’s accompanied by dryness, burning, or urinary symptoms. This helps distinguish GSM-related dyspareunia from other causes of pelvic pain that may need different treatment.